Nuvalent (NUVL) CFO sells 11,430 shares after option exercise under 10b5-1 plan
Rhea-AI Filing Summary
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom exercised stock options for 11,430 shares of Class A common stock at an exercise price of $1.08 per share. On the same date, she sold 11,430 shares in open-market transactions at weighted average prices between $103.81 and $106.69.
The filing shows these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating the sales were scheduled in advance. Following the transactions, Balcom directly holds 85,533 shares of Nuvalent Class A common stock.
Positive
- None.
Negative
- None.
Insights
CFO executes routine option exercise-and-sell under 10b5-1 plan.
The Nuvalent CFO exercised 11,430 stock options at an exercise price of $1.08 per share and sold the same number of shares around $104–$106. This is a classic exercise-and-sell pattern converting equity awards into cash.
The filing notes the trades were made under a Rule 10b5-1 trading plan adopted on December 23, 2025, suggesting they were pre-scheduled rather than opportunistic. After selling, she still holds 85,533 shares directly, so the disposals represent only a portion of her equity exposure.
There are no remaining derivative positions listed in this filing, and the option underlying these shares is fully vested. Overall, this appears to be routine liquidity management rather than a signal of a major change in insider sentiment.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 11,430 | $0.00 | -- |
| Exercise | Class A Common Stock | 11,430 | $1.08 | $12K |
| Sale | Class A Common Stock | 3,544 | $104.39 | $370K |
| Sale | Class A Common Stock | 5,417 | $105.30 | $570K |
| Sale | Class A Common Stock | 2,469 | $106.18 | $262K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.81 to $104.79, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.84 to $105.83, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.85 to $106.69, inclusive. The shares underlying this option are fully vested.